Amphastar Pharmaceuticals, Inc. (AMPH) vs Kardigan, Inc. (KARD)
A side-by-side comparison of Amphastar Pharmaceuticals, Inc. and Kardigan, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMPH
Amphastar Pharmaceuticals, Inc.
$25.91HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
KARD
Kardigan, Inc.
$13.49HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — AMPH vs KARD
growth of $100 · dividends reinvested · last 1yAMPH +30.7% (+30.7%/yr)KARD -30.7% (-30.7%/yr)AMPH compounded faster over this window
AMPH KARD
AMPH vs KARD: by the numbers
- •KARD is the larger company ($1.21B vs $1.14B market cap).
- •AMPH is profitable (10.76% net margin) while KARD runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | AMPH | KARD |
|---|---|---|
| P/E ratio | 15.33 | N/A |
| Forward P/E | 8.72 | N/A |
| PEG ratio | 0.11 | N/A |
| P/S ratio | 1.56 | N/A |
| P/B ratio | 1.49 | 1.96 |
| EV / EBITDA | 8.95 | N/A |
| FCF yield | 13.38% | N/A |
Profitability
| Metric | AMPH | KARD |
|---|---|---|
| Gross margin | 47.68% | 0.00% |
| Operating margin | 15.66% | 0.00% |
| Net margin | 10.76% | 0.00% |
| ROE | 10.23% | N/A |
| ROIC | 5.93% | -57.11% |
Growth (annualized)
| Metric | AMPH | KARD |
|---|---|---|
| Revenue CAGR (5Y) | 13.71% | N/A |
| EPS CAGR (5Y) | 134.23% | N/A |
| FCF CAGR (5Y) | 23.90% | N/A |
| Total return CAGR (5Y) | 6.13% | N/A |
Frequently asked
- Is AMPH or KARD more profitable?
- AMPH runs the higher net margin — AMPH at 10.76% versus KARD at 0.00%.
Go deeper
Dig into the metrics
Amphastar Pharmaceuticals P/E ratioAmphastar Pharmaceuticals ROEKardigan ROEAmphastar Pharmaceuticals operating marginKardigan operating marginAmphastar Pharmaceuticals revenue growthKardigan revenue growthAmphastar Pharmaceuticals free cash flowKardigan free cash flow
Amphastar Pharmaceuticals & Kardigan appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.